As COVID-19 vaccine sales continue to decline, Moderna and BioNTech—two of the leading mRNA vaccine makers—are charting different futures for their businesses.

Moderna: Leaner Strategy, Delayed Break-Even

Moderna is doubling down on mRNA as its core focus. However, the company is facing financial pressures and has adjusted its outlook:

• Operating break-even delayed to 2028, two years later than previously projected.

• R&D budget reduced by $4 billion, down to $16 billion through 2028.

• Moderna aims to streamline its operations and maintain discipline, according to CEO Stéphane Bancel.

Despite these cuts, the company is moving forward with several mRNA-based programs, including combination vaccines and personalized cancer therapies.

BioNTech: Expanding Beyond mRNA

BioNTech, based in Germany, is taking a broader approach. The company sees mRNA as just one tool among many in its immunotherapy pipeline.

• It is diversifying its research across cancer treatments, including cell and antibody therapies, small molecules, and next-generation immunomodulators.

• BioNTech plans to invest in biopharma acquisitions and has over 30 oncology trials underway.

CEO Uğur Şahin says the company’s focus is on long-term innovation beyond infectious diseases.

Vaccine Sales and Market Shifts

• Both Moderna and BioNTech saw massive revenue during the pandemic, but sales have plummeted.

• Moderna expects $4 billion in COVID vaccine sales in 2024, a sharp decline from its peak of $18.4 billion in 2022.

• BioNTech has not given specific 2024 projections but also anticipates a drop.

Investors are watching closely as both companies transition from pandemic-era highs to post-COVID realities.